News
-
-
-
COMMUNIQUÉ DE PRESSE
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Therapeutics appoints Haywood Securities Inc. as strategic advisor to support investment initiatives. Company progressing with Phase 2B clinical trials for psychedelic medicine MB22001 -
-
-
COMMUNIQUÉ DE PRESSE
Mindbio Therapeutics CEO Issues Letter To Shareholders
MindBio Therapeutics Corp. issues shareholder update on Phase 2B clinical trials progress, focusing on treating Major Depressive Disorder & Advanced Stage Cancer - End of Life Distress related Depression and Anxiety with MB22001 drug -